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Abstract
Background: Calcium deficiency is a global public-health problem. Although the initial stage of calcium deficiency
can lead to metabolic alterations or potential pathological changes, calcium deficiency is difficult to diagnose
accurately. Moreover, the details of the molecular mechanism of calcium deficiency remain somewhat elusive.
To accurately assess and provide appropriate nutritional intervention, we carried out a global analysis of metabolic
alterations in response to calcium deficiency.
Methods: The metabolic alterations associated with calcium deficiency were first investigated in a rat model, using
urinary metabonomics based on ultra-performance liquid chromatography coupled with quadrupole time-of-flight
tandem mass spectrometry and multivariate statistical analysis. Correlations between dietary calcium intake and the
biomarkers identified from the rat model were further analyzed to confirm the potential application of these
biomarkers in humans.
Results: Urinary metabolic-profiling analysis could preliminarily distinguish between calcium-deficient and non-
deficient rats after a 2-week low-calcium diet. We established an integrated metabonomics strategy for identifying
reliable biomarkers of calcium deficiency using a time-course analysis of discriminating metabolites in a low-
calcium diet experiment, repeating the low-calcium diet experiment and performing a calcium-supplement
experiment. In total, 27 biomarkers were identified, including glycine, oxoglutaric acid, pyrophosphoric acid, sebacic
acid, pseudouridine, indoxyl sulfate, taurine, and phenylacetylglycine. The integrated urinary metabonomics analysis,
which combined biomarkers with regular trends of change (types A, B, and C), could accurately assess calcium-
deficient rats at different stages and clarify the dynamic pathophysiological changes and molecular mechanism of
calcium deficiency in detail. Significant correlations between calcium intake and two biomarkers, pseudouridine
(Pearson correlation, r = 0.53, P = 0.0001) and citrate (Pearson correlation, r = -0.43, P = 0.001), were further
confirmed in 70 women.
Conclusions: To our knowledge, this is the first report of reliable biomarkers of calcium deficiency, which were
identified using an integrated strategy. The identified biomarkers give new insights into the pathophysiological
changes and molecular mechanisms of calcium deficiency. The correlations between calcium intake and two of the
biomarkers provide a rationale or potential for further assessment and elucidation of the metabolic responses of
calcium deficiency in humans.
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Background
Calcium deficiency is a global public-health problem, espe-
cially in developing countries [1,2]. In China, the Nutrition
and Health Status Survey in 2002 indicated that less than
10% of Chinese citizens had an adequate dietary intake of
calcium; the average intake was 391 mg/day, which is only
41% of the recommended intake [3-5]. Chronic untreated
calcium deficiency can cause many severe consequences,
including osteomalacia (osteopenia) [6], rickets [7-9], and
osteoporosis [2,10,11], and has received worldwide atten-
tion [2,5]. However, the diagnosis of calcium deficiency,
particularly in the initial stages, is easily missed because
this state is asymptomatic and does not lead to obvious
pathological changes. However, even in the initial stage,
metabolic alterations or potential dysfunctions have
already occurred.
A number of methods are currently used to assess cal-
cium nutrition status, including epidemiological survey,
calcium-balance study [12-14], serum biochemical analysis
[15,16], and radiological examination [17]; however, none
of these is suitable for large-scale screening of calcium
deficiency in a population. A calcium metabolic-balance
study based on the dual-trace stable isotope technique is
the classic method, and is considered the most effective
method of assessing calcium nutrition status; however,
this method is labor-intensive, lengthy, and costly [18].
Serum biochemistry testing is an unpleasant and invasive
examination, especially for children, and its sensitivity and
specificity are not always satisfactory [15,16]. Radiological
changes or bone changes reflect only severe calcium defi-
ciency, at which point there has already been serious
damage to the body. Therefore, radiological examination,
in general, cannot provide a diagnosis of calcium defi-
ciency during the early stages, unless there is pathological
injury to bone [17]. Moreover, a detailed understanding of
the molecular mechanism of calcium deficiency has
remained somewhat elusive. For the aforementioned rea-
sons, a sensitive and non-invasive tool is needed to assess
calcium nutrition status accurately and to identify biomar-
kers that can elucidate the mechanisms underlying
calcium deficiency.
Metabonomics, which involves ‘the quantitative mea-
surement of the global, dynamic multi-parametric meta-
bolic response of living systems to pathophysiological
stimuli or perturbations of whatever source’ [19] is an
emerging science. Metabonomics has shown considerable
potential in many applications, including identification of
biomarkers, diagnosis, and prediction of disease, and eluci-
dation of the dynamic responses of organisms to disease
or environmental changes [20-26]. Owing to its high chro-
matographic resolution, high sensitivity, and rapid separa-
tion, ultra-performance liquid chromatography (UPLC)
coupled with mass spectrometry (MS) has been used
widely in metabonomics to investigate subtle metabolite
alterations in complex mixtures [27-30]. Complex three-
dimensional datasets (for example, retention time, mass:
charge ratio, and intensity) with thousands of detectable
ions can be obtained when biological specimens are ana-
lyzed using UPLC-MS. To reduce the complexity of MS
spectra, simplify the data interpretation, and screen the
potential biomarkers, investigators have used multivariate
statistical methods such as principal component analysis
(PCA) and partial least-squares discriminant analysis
(PLS-DA) for metabonomics studies [31].
As a rule, urine is the best biological fluid to use for
studying nutrient intake or identifying biomarkers. Urine
is essentially the body’s liquid waste repository, and any
endogenous or exogenous metabolites that are not needed
or are present in excess may be found in the urine [32].
Therefore, more compounds can be found in urine than
in any other biological matrix. In addition, compared with
other biological specimens, urine collection is non-invasive
and is not volume-limited. Further, urine can easily be
sampled in a serial manner, which allows the temporal
metabolic changes to be studied [33]. Thus, urine is a key
biological matrix in metabolic-profiling studies, and is
considered a potential source of biomarkers. Urinary
metabonomics have proven to be of great value in studies
of drug toxicology [20,34], nutrition metabolism [35,36],
and diagnosis of several diseases, including colorectal can-
cer [28,37], bladder cancer [38], and prostate cancer [39].
In the current study, we carried out a urinary metabo-
nomics study on calcium-deficient rats, using UPLC and
quadrupole time-of-flight tandem mass spectrometry
(Q-TOF MS/MS) coupled with multivariate statistics to
identify reliable biomarkers and to explore the metabolic
alterations associated with the initiation and progression
of calcium deficiency. We verified the reproducibility
and reliability of the calcium-deficient model and bio-
markers using a repeated low-calcium study, and we
investigated the effect of calcium supplementation on
the urinary metabolic profiling of calcium deficiency.
We elucidated the implicated biological mechanisms
and the biochemical pathways of the identified biomar-
kers, and analyzed the possible molecular mechanisms
underlying the calcium deficiency. Furthermore, correla-
tions between dietary calcium intakes and the identified
biomarkers from rat models were investigated for their
potential application to humans.
Methods
Ethics approval
The study was approved by the Harbin Medical Univer-
sity Institutional Animal Care Committee and performed
in accordance with the Harbin Medical University guide-
lines for the care and use of laboratory animals.
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Chemicals and reagents
The products used in this study were high-performance
liquid chromatography (HPLC)-grade acetonitrile and
methanol (Honeywell Burdick & Jackson, Muskegon,
MI, USA), HPLC-grade formic acid (Beijing Reagent
Company, Beijing, China), and leucine-enkephalin
(Sigma-Aldrich, St Louis, MO, USA). Ultrapure water
was prepared in our laboratory (Ultra Clear System; Sie-
mens Water Technologies, Nuremberg, Germany). Bio-
marker standards of the highest grade available were
obtained from commercial sources.
Animal experiments
Male Wistar rats aged 4 weeks (70 ± 10 g body weight;
Shanghai Laboratory Animal Co. Ltd., Shanghai, China)
were housed in individual metabolism cages at 21 ± 2°C
and 50 ± 5% relative humidity with free access to food
and distilled water for an adaptation period of 7 days.
Food intake and body weight were recorded weekly.
Experiment I
The rats were divided randomly into two groups and fed
on either a diet with either normal (AIN-93G Growth
Purified Diet containing 0.50% (w/w) calcium) or low
(AIN-93G Growth Purified Diet containing 0.15% (w/w)
calcium) levels of calcium for 12 weeks (see Additional
file 1). The low-calcium group (LCG) was the calcium-
deficiency model (n = 24) and the normal-calcium group
(NCG was the control (n = 24). Once a week, 24-h urine
samples were collected in the metabolism cages for the
metabonomics study. All urine samples were separated by
centrifugation at 3,000 rpm (835 g) for 10 minutes, and
the supernatant was stored at -80°C. At weeks 2, 4, 6, 8, 10
and 12, 24-h urine and feces samples were taken over 3
consecutive days from eight rats for the calcium meta-
bolic-balance study. After the volumes of urine and the
weights of feces were measured, they were stored at -80°C
until measurement of calcium. At the end of weeks 4, 8,
and 12, eight rats were selected randomly from each
group, fasted for 12 hours, anesthetized by intraperitoneal
injection of sodium pentobarbital (40 mg/kg body weight),
and then killed by bloodletting. Blood samples were taken
from the abdominal aorta, and immediately separated by
centrifugation at 3,000 rpm (835 g) for 15 minutes. The
sera were prepared for biochemical analysis. The left
femur of each rat was isolated by dissection, and freed
from the muscle and connective tissue.
Serum and urine analysis Levels of serum calcium,
phosphorus and alkaline phosphatase (AP) were measured
with commercial kits (Nanjing Jiancheng Bioengineering
Institute, Nanjing, China) using an automatic biochemical
analyzer (AUTOLAB PM 4000; AMS Corporation, Rome,
Italy). ELISA was used to assay serum parathyroid hor-
mone (PTH; Alpco 31-IPTMS-E01 Mouse/Rat Intact PTH
EIA (96 wells); ALPCO Diagnostics, Salem, NH, USA;
inter-assay/intra-assay percentage coefficient of variation
(% CV) < 6% and < 8%, respectively; detection limit 1.0
pg/ml), rat fibroblast growth factor 23 (FGF23, catalog
number E90746Ra; % CV < 5% and< 8%, respectively;
detection limit 6.1 pg/ml) and 1,25(OH)2D3 (catalog num-
ber: E90467Ge; %CV < 5% and < 7%, respectively; detec-
tion limit 4.1 pg/ml) (both Uscn Life Science Inc., Wuhan,
China).
Calcium-balance study determination The detailed
experiment procedure has been described previously
[13]. The calcium contents of urine, feces, and diet were
measured with an atomic absorption spectrophotometer
(AA-7010; East & West Analytical Instruments, Inc.
Beijing, China).
Bone-mineral density measurement The bone-mineral
density (BMD) of the rat femurs was measured using
dual energy X-ray absorptiometry (Norland XR-36
DEXA System; Cooper Surgical, Trumball, CT, USA) in
the Second Affiliated Hospital of Harbin Medical Uni-
versity (Nangang District, China).
Experiment II
Experiment II was designed to verify the reproducibility
and reliability of the calcium-deficient model and the iden-
tified biomarkers from experiment I. Thirty-six rats were
divided randomly into two groups, NCG (n = 12) and
LCG (n = 24), as before, and the diets described for experi-
ment I were supplied to the two groups for 8 weeks. At
the end of week 8, the LCG rats were divided randomly
into two sub-groups: the maintained low-calcium group
(MLCG; n = 12) and the calcium-supplementation group
(CSG; n = 12). The CSG rats were fed a different diet,
with a calcium content of 1.5% (w/w) (see Additional file
1), while the diets supplied for the NCG and MLCG rats
were unchanged. All rats were fed for another 4 weeks.
The 24-h urine samples were collected as described for
experiment I during weeks 1-12.
Global metabolic-profiling analysis of rat urine by
UPLC/Q-TOF MS/MS
Sample preparation
Urine samples were allowed to thaw at room tempera-
ture, diluted 1:1 (v/v) with water, mixed by vortex for
1 minute, and then separated by centrifugation at
12,000 rpm (13362 g) for 10 minutes. The supernatants
were then transferred to autosampler vials.
UPLC conditions
Chromatographic separation was performed on a 1.8 μm
T3 column (ACQUITY (HSS); Waters Corp., Milford,
MA, USA; 2.1 mm × 100 mm) equipped with a UPLC sys-
tem (ACQUITY UPLC; Waters Corp., USA). The tem-
peratures of the column and autosampler were maintained
at 35°C and 4°C, respectively. A sample (2 μl) of the urine
supernatant obtained by centrifugation was injected onto
the column at a flow rate of 0.35 ml/min. The mobile
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phase consisted of water containing 0.1% formic acid
(solution A) and acetonitrile (solution B). The elution gra-
dient was as follows: 2% B for 0.5 minutes; 2 to 20% B
over 0.5 to 6.0 minutes; 20 to 35% B over 6.0 to 7.0 min-
utes; 35 to 70% B over 7.0 to 9.0 minutes; 70 to 98% B
over 9.0 to 10.5 minutes; 98% B for 2.0 minutes;, then
return to 2% B for 6.0 minutes. Once the initial settings
were established, the column was equilibrated for 2.0 min-
utes. Acetonitrile was run every fifth sample as a blank
solution, and the urine samples in the two analysis batches
(experiment I and II) were injected alternately as five NCG
and five LCG samples.
Mass spectrometry conditions
Q-TOF MS/MS was performed with a mass spectrometer
(Micromass Q-TOF mass spectrometer; Waters Corp.,
Manchester, UK) using an electrospray ionization (ESI)
interface with the ESI source operated in the negative ion
mode (ESI-). The analytical parameters were as follows:
capillary voltage, 2800 V; sample cone voltage, 35 V; colli-
sion energy, 6 eV; source temperature, 100°C; desolvation
gas (nitrogen) flow, 650 L/h; desolvation temperature,
320°C; cone gas (nitrogen) flow, 50 l/h; collision gas,
argon; MCP detector voltage, 2200 V. The Q-TOF mass
acquisition rate was set at 0.4 seconds with an interscan
delay of 0.1 second. The scan mass range was from 50 to
1000 m/z. The Q-TOF MS/MS data were collected in cen-
troid mode, using the lock spray to ensure accuracy and
reproducibility. A concentration of 200 pg/ml leucine-
enkephalin was used as lock mass (m/z 554.2615) in ESI-.
The lock spray frequency was set at 10 seconds, and the
lock mass data were averaged over 10 scans for correction.
The MS/MS spectra of potential biomarkers were
obtained by UPLC-MS/MS.
Data processing
The raw data were imported into MarkerLynx software
(which is incorporated in the MassLynx software; version
4.1; SCN 714; Waters Corp., USA). The MarkerLynx
ApexTrack peak integration was used for peak detection
and alignment. The ApexTrack peak parameters were set
as follows: peak width at 5% height, 1 second, and peak-
to-peak baseline noise (calculated automatically). Collec-
tion parameters were set as follows: mass window, 0.05
Da; retention time window, 0.2 minutes; minimum inten-
sity, 80; noise elimination level, 6.0; deisotope data, Yes.
Data were only used for the period 0.4 to 10.5 minutes;
that is, up to the point at which the column-washing
phase of the analysis started. After being recognized and
aligned, the intensity of each ion was normalized to the
summed total ion intensity of each chromatogram, to take
into account the variation in urine concentration and
volume. The data-reduction process was handled in accor-
dance with the ‘80% rule’ [40]. The three-dimensional data
including peak number (RT-m/z pair), sample name, and
normalized peak areas were exported to the EZinfo soft-
ware (version 2.0.0.0; June 5 2008; Waters Corp., USA) for
multivariate statistical analysis. The data were mean-cen-
tered and Pareto-scaled before multivariate statistical ana-
lysis. PCA, an unsupervised multivariate statistical
approach, can reduce the dimensionalities of complex
datasets and provide an overview of all observations in
data tables, such as groupings, trends, and outliers of the
different groups of samples [30,31]. The PLS method was
used for the analysis of time changes [24]. After an initial
overview of the UPLC/Q-TOF-MS data, the supervised
partial least-squares discriminant analysis (PLS-DA) and
orthogonal projection to latent structures discriminant
analysis (OPLS-DA) were applied to visualize the maximal
difference associated with calcium deficiency for each
LCG versus NCG at all time points. A default seven-fold
(Leave-1/7th Samples-Out) cross-validation procedure and
testing with 100 random permutations were performed to
avoid the over-fitting of supervised PLS-DA models, using
SIMCA-P software (version 11.5; Umetrics AB, Umeå,
Sweden).
Identification of biomarkers and metabolic pathway
analysis
The probable empirical formulas of the biomarkers were
first derived based on accurate mass measurement (mass
error of <20 ppm) and by considering the relative intensi-
ties of the isotope peaks through the high-resolution MS
spectra. The MassFragment™ application manager (Mas-
sLynx v4.1, Waters Corp., USA) was used to facilitate the
MS/MS fragment ion-analysis process by way of chemically
intelligent peak-matching algorithms. The identification of
potential biomarkers was achieved by comparison with free
online databases, such as ChemSpider (http://www.chem-
spider.com), the Human Metabolome Database (HMDB)
(http://www.hmdb.ca), Metlin (http://metlin.scripps.edu/)
and Pubchem (http://pubchem.ncbi.nlm.nih.gov/), using
exact mass and MS/MS spectra. Finally, the biomarkers
were further confirmed by standard compounds based on
both retention times and MS/MS spectra.
The implicated pathways of biomarkers were inter-
preted using databases, including HMDB and KEGG.
Human study
Because the ultimate goal of this non-invasive technique is
to screen for calcium deficiency in humans, we further
confirmed the potential application of three of the biomar-
kers identified from the rat models in calcium-deficient
human subjects. Post-menopausal women have been
reported to be the core of the population at risk for cal-
cium deficiency, thus, to investigate the correlations
between calcium intake and the identified biomarkers of
calcium deficiency, we chose post-menopausal women as
the subjects in this study.
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The project was approved by the Ethics Committee of
Harbin Medical University, and informed consent was
obtained from all subjects before entry into the study.
In total, 70 participants who had lived in Harbin for
more than 5 years were randomly recruited (from Hon-
gqi Community Health Service Center, Harbin City,
China). All the participants were women aged 50 to 64
years (mean ± SD 56.55 ± 3.8 years), had natural meno-
pause for up to 1 year or were post-menopausal.
The exclusion criteria included subjects with: any condi-
tions affecting calcium absorption or metabolism, such as
hyperparathyroidism, inherited bone disease, ovarian sur-
gery, gastrointestinal resection, thyroid resection, malab-
sorption, or diseases of the digestive tract; (2) other
diseases, such as coronary heart disease, stroke, diabetes,
cancer, thyroid or parathyroid disease, and chronic disease
of the liver or kidney; or current treatment with hormone-
based drugs or other medications such as estrogen.
The average calcium intake per day was derived from 3
days of weighed dietary records for each woman, and 24-h
urine samples were collected from all subjects. The nor-
malized peak areas of the biomarkers were detected for
quantitative analysis by UPLC/Q-TOF MS/MS.
Statistical analysis
Serum biochemical indicators and BMDs of the LCG and
NCG rats were expressed as the mean ± SD. Differences
between the two groups were analyzed by the independent
t-test and Mann-Whitney U-test. Correlations between
dietary calcium intake and the biomarkers in human sub-
jects were examined by linear regression analysis. Log-
transformed values were used for the skewed distributions
of the biomarkers. A two-tailed value of P <0.05 was con-
sidered significant. All analyses including the error bars of
three unique metabolites were performed using SPSS soft-
ware (version 16.0; SPSS Inc., Chicago, IL, USA).
Results
Serum biochemical indicators and bone-mineral density
There was a significant difference between the LCG and
NCG rats for mean serum PTH and 1,25(OH)2D3 at
week 4, for serum AP, PTH, and 1,25(OH)2D3 at week 8,
and for all of the serum indicators plus BMD at week 12
(Table 1). The serum level of FGF23 at week 12 was signif-
icantly higher in the LCG rats compared with the NCG
rats (P = 0.002). There was no significant difference
between the two groups in dietary intake or body weight
at any time point. Calcium excretion in urine and feces,
and calcium intake were significantly lower in the LCG
rats compared with the NCG rats at weeks 2, 4, 6, 8, 10,
and 12 (P<0.05) (see Additional file 2). Although the
apparent absorptivity of calcium was significantly higher
in the LCG rats compared with the NCG rats at weeks 2,
4, 6, 8, 10, and 12, the retention (absorption) of calcium
was significantly lower in the LCG rats (P<0.05). These
results confirmed the successful establishment of the cal-
cium-deficient rat model in our study.
Quality assessment of the metabonomics platform
To verify the reproducibility and reliability of the data, a
representative pooled quality control (QC) sample was
prepared by mixing equal volumes of the urine samples
from five LCG rats and five NCG rats; this was analyzed
as every 15th sample throughout the analytical run.
An initial overview of the quality of the analytical run
was obtained by PCA of the sample dataset that included
the QC injections. The QC results were clustered tightly
in the middle of the scores plot (see Additional file 3; red
stars). The relative standard deviations (RSD; %) of the
retention time and peak area in intra-batch/inter-batch
assays ranged from 0 to 0.73 and 0.8 to 4, respectively, in
the intra-batch assay, and from 0.1 to 2.7 and 1.5 to 6.2,
respectively in the inter-batch assay (see Additional file 3).
The results showed that the stability of the metabonomics
platform was excellent throughout the run, and was suffi-
cient to ensure the data quality for further global metabo-
nomics analysis.
Urinary metabolic-profiling analysis of experiment I
All of the urine samples (n = 384) from weeks 1-12 col-
lected in experiment I were analyzed by UPLC/Q-TOF
MS/MS in ESI-. Representative chromatograms of base-
line peak intensity (BPI) of urine indicated that the
metabolites of the samples attained suitable separation
on the UPLC T3 column by gradient elution (Figure 1).
After the data reduction was performed in accordance
with the ‘80% rule’, 3131 variables were used for multi-
variate statistical analysis.
To visualize the general clustering trends between the
two groups, PCA and PLS-DA were applied to the urin-
ary metabolic profiling obtained from the NCG and
LCG rats. The PCA scores plot (the R2Y value repre-
sents the goodness of fit of the model, and the Q2 value
represents the predictability of the models) for the first
two components: R2Y = 0.280, Q2 = 0.236) reflected a
separation trend between the LCG and NCG rats
(Figure 2A). As shown by the PLS-DA scores plot (for
the first five components, R2Y = 0.826 and Q2 = 0.687;
Figure 2B), the NCG and LCG rats could be separated
into distinct clusters, with distinct metabolic alterations
between the two groups. To assess the risk that the cur-
rent PLS-DA model was spurious, the permutation test
for PLS-DA was applied. All R2X and Q2 values to the
left were lower than the original points to the right (see
Additional file 4), showing that the PLS-DA model was
valid. The results suggested that the low-calcium diet
had led to the urinary metabolite alterations in our rat
model.
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To visualize the trend changes between the two groups
over time, batch PLS analysis was applied to the urinary
metabolic profiling obtained from the LCG and NCG
rats. Excluding the first week, the batch PLS scores plot
(Figure 3) showed a clear separation tendency between
the two groups from weeks 2 to 12. To investigate the
global metabolic alterations between the two groups, the
UPLC/Q-TOF MS/MS data for all time points were ana-
lyzed by PCA. A small separation tendency between the
two groups was seen at week 2 (Figure 4A), with clear
separation between the two groups at week 4 (Figure 4B).
The metabolic profiling had changed more obviously at
week 9 (Figure 4C), which led to further separation
between the two groups. Based on these results, the urin-
ary metabolite profiling of the LCG rats was altered by
the second week of the low-calcium diet. These results
provide evidence of the important potential value of urin-
ary metabolic profiling for the diagnosis of calcium
deficiency.
To investigate the dynamic and continuous alteration
in urinary metabolites during the initiation and progres-
sion of calcium deficiency, a metabolic trajectory analysis
was conducted using PCA for the global urinary meta-
bolic-profiling analysis of the LCG rats during weeks 1
Table 1 Serum biological indicators and bone-mineral density between rats on the normal-calcium diet and rats on
thelow-calcium diet.
Normal-calcium group Low-calcium group
Week 4 Week 8 Week12 Week 4 Week 8 Week 12
Calcium, mmol/l 2.53 ± 0.26 2.55 ± 0.19 2.56 ± 0.28 2.55 ± 0.23 2.51 ± 0.17 2.31 ± 0.28*
Phosphorus, mg/l 9.38 ± 1.94 9.29 ± 2.35 9.17 ± 2.11 9.29 ± 2.03 8.85 ± 1.60 8.67 ± 2.03
AP, U/l 85.8 ± 21.0 82.4 ± 14.2 80.1 ± 16.3 96.6 ± 17.9 111.7 ± 20.3* 117.8 ± 17.9*
PTH, pg/ml 45.6 ± 6.08 42.3 ± 2.22 31.2 ± 1.75 59.4 ± 6.87* 53.7 ± 1.95* 42.8 ± 2.13*
1,25, OH2D3, pg/ml 70.7 ± 14.9 71.6 ± 18.1 72.2 ± 19.9 87.2 ± 23.1* 120.2 ± 26.4* 121.3 ± 19.1*
FGF23, pg/ml - - 211 ± 9.28 - - 234 ± 14.44*
BMD, g/cm2 0.258 ± 0.02 0.285 ± 0.02 0.298 ± 0.02 0.254 ± 0.03 0.277 ± 0.01 0.262 ± 0.03*
Abbreviations: AP, alkaline phosphatase; BMD, bone-mineral density; FGF23, fibroblast growth factor 23; LCG, low-calcium group; NCG, normal-calcium group,
PTH, parathyroid hormone. *Significant differences (P<0.05) for mean values of LCG compared with NCG at the same time points.
Figure 1 Representative ultra-performance liquid chromatography and quadrupole time-of-flight tandem mass spectrometry (UPLC/Q-
TOF MS/MS)-based peak intensity chromatogram of rat urine in electrospray ionization (ESI) negative ion mode. (A) Rat on normal-
calcium diet; (B) rat on low-calcium diet. BPI, baseline peak intensity.
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to 12. The observations at weeks 4 to 8 and 9 to 12 mark-
edly deviated from those at weeks 1 to 3 (Figure 5). There
were three clear clusters for the plots of the metabolic
trajectory scores for weeks 1 to 3, 4 to 8, and 9 to 12,
which implied that there were three different develop-
mental stages for the progression of calcium deficiency,
that is, an early stage (weeks 1 to 3), a middle stage
(weeks 4 to 8) and a late stage (weeks 9 to 12). These
results showed that a continuous low-calcium diet could
induce persistent underlying metabolic variations and
worsening of calcium deficiency.
To identify the difference in metabolites between the
NCG and LCG rats, OPLS-DA models were constructed
for all time points. Discriminating variables were selected
primarily according to their variable importance in projec-
tion values (VIP > 1.5) and S-plot by OPLS-DA. The dis-
criminating variables obtained from the OPLS-DA models
were further validated by the Wilcoxon test (P<0.05).
Although hundreds of discriminating variables were
selected as potential markers at each time point, only a
small percentage were shared across different time points.
It was expected that the real biomarkers should change in
accordance with the progression of calcium deficiency,
therefore, only the biomarkers with regular trends of
change were considered as potential biomarkers in this
study.
Three distinct changing trends for potential biomarkers
were obtained by time-course analysis. As shown in
Figure 6A1 and 6A2, Biomarkers whose peak areas were
consistently higher or lower in the LCG rats compared
with the NCG rats throughout the experiment (see
Figure 6A1, 6A2)., were defined as type A. Biomarkers
whose peak areas were lower in the LCG rats than in the
NCG rats for weeks 2 to 9, and subsequently disappeared
in weeks 10-12, (that is, the he changing trend for the
biomarker was that it appeared at the initial stage and
disappeared at the middle or late stage) were defined as
type B (Figure 6B). Finally, biomarkers whose peak area
Figure 2 Urinary metabolic-profiling analysis of rats in the low-calcium group (LCG) and normal-calcium group (NCG) during weeks 1
to 12. (A) Principal component analysis (PCA) score plots; (B) partial least-squares discriminant analysis (PLS-DA) score plots. LCG rats are
indicated by black triangles and NCG rats by red circles. Each data point represents one subject. Comp, component. t[1], component 1; t[2],
component 2.
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was higher in the LCG rats than in the NCG rats from
week 6 to the end of the experiment were defined as type
C (Figure 6C). Based on these three changing trends, 38
potential biomarkers associated with calcium deficiency
were selected (see Additional file 5).
Urinary metabolic-profiling analysis of experiment II
(repeated low-calcium diet experiment)
The analytical method of urinary metabolite profiling
used in experiment I was used in the repeated low-cal-
cium diet experiment (urine samples, n = 288). Similar
results were obtained for classification trends by PCA,
PLS-DA, batch PLS scores plot, and PCA trajectory ana-
lysis (see Additional file 6), which indicated that the urin-
ary metabolic profiling of calcium-deficient rats had a
high degree of repeatability. These similar results further
confirmed that the cluster between the two groups was
robust and valid, and that the urinary metabolite profiling
of calcium-deficient rats was significantly altered by the
second week of the low-calcium diet. Most of the bio-
markers from experiment I were identified, and these
had the same changing trends as seen in the earlier
experiment. Only nine biomarkers were not seen in the
repeated low-calcium diet experiment, and these were
excluded. Accordingly, the list of markers now comprised
29 potential biomarkers (see Additional file 7).
Urinary metabolic-profiling analysis of experiment II
(calcium-supplement experiment)
Significant changes in several serum biological indicators
and a decreasing trend for BMD were found in the LCG
rats after week 8 (Table 1). Moreover, based on the
metabolic trajectory analysis by PCA (Figure 5), it
seemed that calcium deficiency would progress from the
Figure 3 Batch partial least-squares (PLS) scores plots of urine samples mapped with time. Dashed horizontal lines show two and three
standard deviations (SDs) for the dataset. Low-calcium group (LCG) rats are indicated by black lines and normal-calcium group (NCG) rats by red lines.
Figure 4 Principal component analysis (PCA) score plots of rats in the low-calcium group (LCG) and normal-calcium group (NCG). (A-C)
Week 2, n = 48 (for two components, R2Y = 45.0%, Q2 = 24.1%); week 4, n = 32 (for three components R2Y = 54.6%, Q2 = 27.6%) and week 9,
n = 16 (for three components R2Y = 58.3%, Q2 = 32.1%). The R2Y value represents the goodness of fit of the model, and the Q2 value
represents the predictability of the models. LCG rats are indicated by black squares and NCG rats by red triangles. Each data point represents
one subject. Comp, component. t[1], component 1; t[2], component 2.
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middle stage to the late stage if the LCG rats were kept
on a low-calcium diet after week 8. Therefore, to inves-
tigate the effect of calcium supplementation on the urin-
ary metabolic profiling of calcium-deficient rats, half of
the LCG rats (CSG) were supplied with the 1.5% high-
calcium diet after week 8, while the other half (MLCG)
remained on the low-calcium diet.
The PCA score plots showed that the projections for the
metabolites measured in CSG rats clustered with those of
the LCG rats and deviated from those of the NCG rats
before calcium supplementation at week 8 (Figure 7A).
After calcium supplementation for 1 week, three clusters
were apparent in the urinary metabolic profiling, with the
CSG rats clearly discriminated from both the MLCG and
NCG rats (Figure 7B). This result indicated that the cal-
cium deficiency had been alleviated by the calcium supple-
mentation, but that the calcium metabolism had not yet
returned to normal levels. After calcium supplementation
for 4 weeks, the CSG rats were completely differentiated
from the MLCG rats, and were clustered with the NCG
rats (Figure 7C), indicating that the calcium metabolic
alterations had been largely restored, and that calcium
metabolism was nearly normal.
Accompanying the visual changes in urinary metabolic
profiling, the potential biomarkers also changed signifi-
cantly in the CSG rats compared with tthe MLCG rats.
For example, the peak area of the biomarker with m/z
74.0238 in the CSG rats decreased significantly at the end
of week 1 and disappeared at the end of week 2. This was
the type of calcium-deficiency biomarker that we were
seeking. If there were still significant differences in the
peak areas of biomarkers between the CSG and NCG rats
at week 4 of calcium supplementation, these biomarkers
were excluded from the biomarker list. Based on this, 2
more potential biomarkers were excluded, leaving 27
potential calcium-deficiency biomarkers (Table 2). When
these were assessed, it was found that, compared with the
NCG rats, 12 biomarkers were upregulated and 15 bio-
markers were downregulated in the LCG rats.
Identification of biomarkers
In this study, 27 metabolites were selected as calcium defi-
ciency biomarkers. Eleven biomarkers were confirmed by
comparing their retention times and MS/MS fragmenta-
tion patterns with those of the standards (Table 2).
Detailed identification experiments using Q-TOF MS/MS
and standards to elucidate the elemental composition of
each biomarker (for example, cAMP) were performed (see
Additional file 8). Ten further biomarkers were identified
by searching several free online databases. Hence, 21 bio-
markers were identified (Table 2). Six more biomarkers
were determined by exact mass, isotopic distribution, and
mass spectra fragmentation patterns, using MassFragment
software (for detailed data, see Additional file 9).
Correlation between dietary calcium intake and each
metabolite in human
The average dietary calcium intake of the 70 women was
483 ± 248 mg (range 164 to 1517 mg). There were signifi-
cant correlations between dietary calcium intake and urin-
ary levels of citrate (Pearson correlation, r = -0.43, P =
0.001) and pseudouridine (Pearson correlation, r = 0.53,
P = 0.0001) (Figure 8). However, no significant correlation
between urinary pyrophosphoric acid (Pearson correlation,
r = 0.15, P = 0.413) and dietary calcium intake was found
(Figure 8).
Figure 5 Metabolic trajectory scores plots by principal component analysis (PCA) model derived from the urine of rats on low-calcium
diet. Samples were collected during weeks 1 to 12. Black triangle: weeks 1 to 3; red star: weeks 4 to 8; blue circle: weeks 9 to 12. Comp,
component. t[1], component 1; t[2], component 2.
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Figure 6 Error bar plots for the peak areas of four potential biomarkers with representative changing trends. The normalized peak area
is shown on the vertical coordinate, and the time points of sample collection on the horizontal coordinate. Error bars represent the means and
95% confidence interval (CI) of the normalized peak areas. Low-calcium group (LCG) rats are indicated by green boxes and normal-calcium
group (NCG) rats by black boxes.
Figure 7 Principal component analysis (PCA) score plots of low-calcium diet rats, normal-calcium diet rats and calcium-supplement
diet rats (n = 36). The maintained low-calcium group (MLCG) rats are indicated by blue circles, the normal-calcium group (NCG) rats by red
circles, and the calcium-supplement group (CSG) by black triangles. The R2Y value represents the goodness of fit of the model, and the Q2 value
represents the predictability of the models. (A) Before calcium supplementation (for six components R2Y = 53.9%, Q2 = 23.4%); (B) after calcium
supplementation for 1 week (for five components R2Y = 55.3%, Q2 = 26.1%); (C) after calcium supplementation for 4 weeks (for five
components R2Y = 55.6%, Q2 = 28.3%). Comp, component. t[1], component 1; t[2], component 2.
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Discussion
Calcium deficiency is reversible when diagnosed at an early
stage. However, without proper intervention, calcium defi-
ciency can develop to an irreversible stage, such as rickets.
Several methods, including epidemiological survey,
calcium-balance study, serum biochemical investigations,
and radiological examination, are currently used for the
assessment of calcium nutrition status. However, none of
these methods is suitable for large-scale population screen-
ing or for the clinical diagnosis of calcium deficiency at an
early stage. Therefore, a non-invasive method and suffi-
ciently sensitive and specific biomarkers are urgently
needed for assessing the presence and progression of cal-
cium deficiency. Urinary metabonomics based on UPLC/
Q-TOF MS/MS has been of great value in the discovery of
biomarkers and the elucidation of the pathogenesis of var-
ious diseases [37-39]. To date, there has been no report of
urinary metabonomics focused on calcium deficiency.
Therefore, this unbiased global urinary metabonomics
study based on UPLC/Q-TOF MS/MS coupled with multi-
variate statistical analysis is the first to identify potential
biomarkers and unravel the molecular mechanisms of cal-
cium deficiency.
As shown by our experiments, there were no significant
changes in the serum levels of phosphate, calcium, or AP
before week 9, but there were changed in PTH and 1,25
(OH)VD3 levels at this point. Although PTH secretion was
exquisitely sensitive to very small changes in serum cal-
cium concentration, PTH is not a specific biomarker of
calcium deficiency. Numerous experiments have shown
that a rise in PTH can be caused by other factors, such as
primary hyperparathyroidism and secondary hyperpar-
athyroidism [41,42]. Although the calcium balance chan-
ged significantly during the study, this method took at












Identity Trendb Onset Disappear Type
1 1.21 191.0173 191.0192 9.9 C6H8O7 Citrate
b ↓ 1 12 A
2 1.20 111.0073 111.0082 8.1 C5H4O3 Ion fragment of citrate
b ↓ 1 12 A
3 0.68 176.9366 176.9354 6.8 H4P2O7 Pyrophosphoric acid
b ↑ 1 12 A
4 0.98 145.0158 145.0137 14.5 C5H6O5 Oxoglutaric acid
c ↓ 1 12 A
5 0.96 175.0251 175.0243 4.5 C6H8O6 Ascorbic acid
b ↓ 1 12 A
6 5.89 192.0629 192.0661 16.7 C10H11NO3 Phenylacetylglycine
c ↑ 1 12 A
7 5.97 74.0238 74.0242 5.4 C2H5NO2 Glycine
b ↑ 1 12 A
8 1.02 101.0237 101.0239 2.0 C4H6O3 Acetoacetic acid
c ↓ 1 12 A
9 6.42 283.0714 283.0679 12.4 C10H12N4O6 Xanthosine
c ↑ 1 12 A
10 6.81 231.0702 231.0657 19.5 C13H12O4 Naphthoxylactic acid
d ↑ 6 12 C
11 9.30 407.2809 407.2797 2.9 C24H40O5 Cholanoic acid
c ↓ 5 12 C
12 1.14 167.0211 167.0205 3.6 C5H4N4O3 Uric acid
b ↓ 1 5 B
13 0.99 293.0520 293.0484 12.3 C9H14N2O7S L-Glutamic acid, N-[[[(1S)-1-carboxy-2-
mercapto-ethyl]amino]carbonyl]-d
↓ 1 12 A
14 1.02 243.0625 243.0617 3.3 C9H12N2O6 Pseudouridine
b ↓ 8 12 C
15 8.19 201.1134 201.1127 3.5 C10H18O4 Sebacic acid
c ↓ 1 7 B
16 6.44 113.0231 113.0239 7.1 C5H6O3 4-Oxo-2-pentenoic acid
d ↑ 1 12 A
17 0.65 124.0059 124.0068 7.3 C2H7NO3S Taurine
b ↓ 2 12 A
18 8.21 199.1352 199.1334 9.0 C11H20O3 6-(2-hydroxycyclopentyl) hexanoic acid
d ↓ 1 12 A
19 6.43 212.0020 212.0018 0.9 C8H7NO4S Indoxyl sulfate
c ↑ 1 8 A
20 6.44 175.0236 175.0243 4.0 C6H8O6 D-glucurono-6,3-lactone
c ↑ 1 12 A
21 7.15 171.1008 171.1008 0 C7H12N2O3 Glycylproline
c ↓ 2 9 B
22 5.87 222.0808 222.0766 18.7 C11H13NO4 N-acetyl-L-tyrosine
c ↓ 2 9 B
23 8.46 113.0964 113.0966 1.8 C7H14O Ethyl isobutyl ketone
d ↓ 1 12 A
24 2.36 328.0451 328.0447 1.2 C10H11N5O6P Cyclic adenosine monophosphate
b ↑ 1 12 A
25 4.31 178.0499 178.0504 2.8 C9H10NO3 Hippuric acid
b ↑ 1 12 A
26 1.08 129.0170 129.0188 14 C5H6O4 Monomethyl fumarate
d ↑ 6 12 C
27 0.67 194.9456 194.9460 2.1 H6P2O8 Phosphoric acid
b ↑ 1 12 A
Abbreviations: RT, retention time (minute). aArrow denoted the increase or decrease of the metabolites in low-calcium diet rat compared with those in the
control rats. Type A: the biomarkers seen throughout the progression of calcium deficiency. Type B: the biomarkers appeared at the initial stage and dizappeared
at the middle or late stage. Type C: the biomarkers seen at the middle or late stage. b Biomarkers confirmed using standard samples. c Biomarkers identified by
tandem mass spectrometry (MS/MS) spectra of databases. d The possible elemental compositions of biomarkers determined based on exact mass data and MS
fragmentation.
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least 3 days to perform. In addition, the serum calcium
level was significantly decreased until week 12, indicating
the body’s strong ability to maintain calcium homeostasis.
Similarly, significant decreases in BMD were not found
until week 12. These results suggest that both serum cal-
cium and bone radiological change can only reflect long-
term or severe calcium deficiency. In contrast to the
serum indicators, urinary metabolic alterations between
the NCG and LCG rats were detected at week 2 using glo-
bal urinary metabolic profiling. This observation was also
confirmed by a calcium-balance study. Moreover, after cal-
cium supplementation for 1 week, the altered calcium
metabolism had been largely restored. These results show
that urinary metabolic profiling has high sensitivity to
subtle metabolic perturbation. We were able to prelimina-
rily distinguish the LCG from the NCG rats by urinary
metabolic-profiling analysis.
To gain insight into the metabolic mechanism of cal-
cium deficiency and to provide an accurate assessment of
calcium nutrition status, reliable biomarkers should be
identified. However, in metabonomics studies, a major
challenge to date has been how to distinguish reliable bio-
markers that are closely associated with the initiation and
progress of disease from those that are altered but are
unrelated to the disease. The ideal strategy for discovering
reliable biomarkers should include a time-course analysis
for discriminating metabolites in a experiment on rats
with low-calcium diet, and subsequent validation of the
candidate biomarkers by a repeated experiment on rats
with low-calcium diet along with a nutrition-supplement
experiment. Therefore, we developed an integrated screen-
ing method consisting of the following steps. First, the dis-
criminating variables with regular and reasonable
changing trends (types A, B and C; Figure 6), were selected
as potential biomarkers by time-course analysis. Second,
the repeatability of biomarkers is crucial for their identifi-
cation and biological interpretation in metabonomics stu-
dies. Thus, to verify the repeatability of biomarkers, the
same urinary metabolic profiling and time-course analysis
of discriminating variables were applied in a repeated low-
calcium experiment. Third, a calcium-supplement experi-
ment based on the low-calcium experiment was used to
confirm the above biomarkers.
As shown by our study results, 27 variables were chosen
as reliable biomarkers of calcium deficiency. Biomarkers
with the type A changing trend (for example, glycine,
sebacic acid) were present throughout the progression of
calcium deficiency. Biomarkers with the type B changing
trend were defined as the specific biomarkers that were
present in the early (for example, uric acid, weeks 1-5),
early and middle (for example, indoxyl sulfate, weeks 1-8)
stages of calcium deficiency. By contrast, biomarkers with
the type C changing trend were defined as the specific bio-
markers that were present in the middle (for example,
cholanoic acid, weeks 5-12), middle and late (for example,
pseudouridine, weeks 8-12) stages. Hence, we concluded
that if significantly increased levels of glycine (type A) and
decreased levels of uric acid (type B) were both detected,
but biomarkers with the type C changing trend were not
detected, this would suggest that the body was in the early
stages of calcium deficiency. If significantly increased levels
of glycine (type A) and indoxyl sulfate (type B), and
decreased levels of ions (cholanoic acid; type C) were all
detected in urine, this would indicate that the body was in
the middle stage of calcium deficiency. Finally, if signifi-
cantly increased levels of glycine (type A) and decreased
levels of uridine (type C) were detected, this would suggest
severe calcium deficiency. These results proved that the
Figure 8 Correlation between calcium intake and two biomarkers. (A, B) The human study enrolled 70 women, and analzed the
correclation between the log (lg) dietary calcium intakes and (A) urine pseudouridine (r = 0.53, P = 0.0001) or (B) citrate (r = -0.43, P = 0.001).
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biomarkers identified by urinary metabolomics were suffi-
cient to assess the level of calcium deficiency at different
stages in the male rat, which cannot be achieved by serum
biochemical analysis. After further validation of several
biomarkers (oxoglutaric acid, phenylacetylglycine, pyro-
phosphoric acid, citric acid, sebacic acid, pseudouridine,
indoxyl sulfate, and taurine) that occur frequently in
humans, these biomarkers could be used alone or in com-
bination as a non-invasive method with greater sensitivity
and specificity for the diagnosis of calcium deficiency.
Based on the biomarkers identified here (Figure 9),
several metabolic pathways seem to be correlated with cal-
cium metabolism. The increased levels of pyrophosphate,
cAMP, and phosphate in the urine of the LCG rats suggest
impaired calcium and phosphorus metabolism. The
increased secretion of PTH in response to the low-calcium
diet was responsible for the activation of adenylate cyclase
and the production of cytoplasmic cAMP and pyropho-
sphate. The activation of this signal-transduction pathway
would induce intracellular calcium mobilization and acti-
vation of the membrane calcium pump, which could result
in an increased concentration of cytoplasmic Ca2+ [43].
Cytoplasmic Ca2+ was transported to the extracellular
fluid of the cell in order to restore serum calcium levels
when the rats were fed a low-calcium diet. By contrast,
increased PTH and 1,25(OH)2 VD3 could promote renal
tubule re-absorption of calcium and inhibit the re-absorp-
tion of phosphorus, thereby reducing urinary calcium
excretion and increasing urinary phosphate excretion.
Increased serum FGF23 led to decreased serum phos-
phorus and increased urine phosphorus levels [44]. There-
fore, increased levels of inorganic phosphates, including
phosphate, pyrophosphate, and cAMP, were found in the
urine samples in this study (Figure 9A).
A high concentration of PTH can promote the transfor-
mation of preosteoclasts and stromal cells into osteoclasts.
Highly active osteoclasts dissolve bone minerals by secret-
ing acid onto the isolated surface, and simultaneously
break down the bone matrix by secreting collagenase and
hydrolase. Increased levels of glycylproline, the end pro-
duct of collagen metabolism, were found when bone col-
lagen was disrupted. Glycylproline can be further digested
by prolidase to glycine and proline, and we found
decreased glycylproline and increased glycine levels in
urine collected from the LCG rats. Glycine is involved in
the synthesis of collagen. Phenylacetylglycine is a glycine
conjugate of phenylacetic acid. Decreased glycylproline
and increased glycine and phenylacetylglycine levels in
urine suggested disruption of bone collagen. The results of
our study suggest that glycylproline, glycine, and phenyla-
cetylglycine could be involved in the metabolic pathway
of the degradation and biosynthesis of bone collagen,
and that the low-calcium diet could have induced disrup-
tion of bone collagen. Ascorbic acid is necessary for the
maintenance of connective tissue and bone, and it is an
electron donor for enzymes involved in collagen hydroxy-
lation [45,46]. D-Glucurono-6,3-lactone participates in the
synthesis of ascorbate. The significant increase of D-glu-
curono-6,3-lactone levels in LCG urine indicates that the
synthesis of vitamin C was reduced because of the lack of
D-glucurono-6,3-lactone, and a decrease in ascorbic acid
levels in the LCG urine was also seen. The decreased
ascorbic acid and increased D-glucurono-6, 3-lactone
levels could be an indication or a possible consequence, of
impaired connective tissue and bone.
PTH induced the demineralization and inhibition of
citrate excretion [47], and reduced citrate excretion was
found in the LCG urine. Citrate has an important role in
bone metabolism and bone diseases [48-50], and it can be
considered a biomarker of calcium deficiency. Citric acid
(citrate) can be formed in the Krebs cycle. Oxoglutaric
acid and acetoacetic acid are the important biological
compounds and are key intermediates in the Krebs cycle,
therefore, the decreased oxoglutaric acid, acetoacetic acid,
and citrate levels found in LCG urine suggest that the
Krebs cycle could be impaired by calcium deficiency.
Xanthosine and uric acid are involved in purine metabo-
lism. The increased xanthosine and decreased uric acid
levels suggest that purine metabolism was possibly related
to calcium metabolism. N-acetyl-l-tyrosine and L-glutamic
acid are amino acids. The alterations of these two metabo-
lites in our study suggest that calcium deficiency could
lead to the abnormal metabolism of amino acid. Sebacic
acid belongs to the dicarboxylic acid, which is involved in
the metabolism of lipids and carbohydrates. Previous
reports have documented that the medium-chain dicar-
boxylic acids (such as sebacic acid) are naturally occurring
substances formed by cytochrome P450-mediated ω-oxi-
dation of fatty acids in the cytosol of cells [51]. The
decreased excretion of sebacic acid in rat urine suggests
that calcium deficiency could impair ω-oxidation of med-
ium-chain monocarboxylic acids. Taurine is a facilitator in
the transport of calcium ions [52,53] and influences bone
metabolism [54]. The decreased taurine levels in the LCG
urine indicate impairment of bone metabolism. In earlier
studies, it was found that indoxyl sulfate could impair
osteoblast function and induce abnormal bone turnover
[55,56]. Our results suggest that osteoblast function and
bone turnover of the LCG rats could be impaired by
increased indoxyl sulfate.
An animal urinary metabonomics study can provide
continuous time-dependent data to allow assessment of
the dynamic metabolic alterations and reveal the time-
dependent pathophysiological changes. For instance,
significantly increased levels of pyrophosphate, cAMP,
glycine, indoxyl sulfate, and xanthosine, and decreased
levels of citrate, oxoglutaric acid, acetoacetic acid, sebacic
acid, and ascorbic acid were seen in the LCG rats in
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week 2, indicating that a 2-week low-calcium diet could
result in metabolic changes in calcium and phosphorus
levels, and in mild disruption of bone, bone collagen and
bone turnover, and osteoblasts. This result is consistent
with the results of the calcium-balance study, which
could further explain the reason for the decrease in cal-
cium excretion in urine and feces and the increase in cal-
cium absorptivity. The peak area of pyrophosphate was
decreased and that of ascorbic acid was increased persis-
tently during weeks 1 to 12 (Figure 6A1, 6A2), indicating
that body calcium homeostasis was gradually disrupted
as the calcium deficiency progressed. Moreover, pseu-
douridine, naphthoxyacetic acid, cholanoic acid, and
monomethyl fumarate in the LCG rats appeared to be
changed significantly after week 6. At this stage, there was
significantly perturbed expression of phosphate, amino
acids, organic acids, fatty acids and purine metabolism,
and disruption of bone, bone collagen, osteoblasts, and the
Krebs cycle in the LCG rats as measured by the urinary
metabonomics study. These results suggest that the nor-
mal patterns of bone resorption and remodeling in the
LCG rats was impaired, thus abnormal bone resorption
and remodeling had led to disorders of bone metabolism
and decreased BMD (Figure 9B). Most of the identified
biomarkers supported the molecular mechanisms and
pathophysiological changes associated with calcium defi-
ciency that have been reported previously. In the current
study, we found, for the first time to our knowledge, that
purine metabolism and the Krebs cycle are possibly related
to calcium deficiency. It is possible that new metabolic
pathways and unknown mechanisms are involved in the
progression of calcium deficiency. Further research
focused on these biomarkers is needed.
Because they allow greater control of conditions to
reduce extrinsic variability, animal models have advantages
over human studies when investigating biomarkers and
elucidating subtle metabolite alterations. Thus, we firstly
identified the calcium-deficient biomarkers from animal
models, before verifying the potential application of three
biomarkers in humans. Significant correlations were found
between dietary calcium intakes and two of the biomar-
kers (pseudouridine and citrate). Because we did not con-
trol for confounding factors, such as gender, age, health
state, disease, and the serum levels of 25(OH)VD3 and
PTH, the true correlations might have been concealed to
some extent.
There were some limitations to our studies. We used
only male rats in the animal study, thus, the gender may
have been a confounder in the metabolomics experiments.
Moreover, the human study in post-menopausal women
regarding the correlations between calcium intake and two
biomarkers provides only a potential application of these
two biomarkers in humans. Large, well-designed studies
(including male and female subjects) that control for con-
founding factors are needed to verify in humans the
potential application of these two biomarkers from our
animal models.
Conclusions
We have identified for the first time reliable biomarkers
of calcium deficiency in male rats, by using a time-course
analysis of discriminating metabolites in a low-calcium
diet experiment, then repeating the low-calcium diet
experiment and performing a calcium-supplement
experiment. The identified biomarkers give new insights
into the pathophysiological changes and molecular
Figure 9 Schematic of altered metabolic pathways associated with calcium deficiency based on urinary metabolites analyzed by ultra-
performance liquid chromatography and quadrupole time-of-flight tandem mass spectrometry (UPLC/Q-TOF MS/MS). (A) Metabolism of
calcium and phosphorus metabolism; (B) Krebs cycle and metabolism of bone collagen, purines and other biomarkers. Biomarkers are shown in
red. Red arrows indicate increased levels and green arrows indicate decreased levels of these metabolites in the low-calcium group (LCG) rats
compared with the control (normal-calcium group; NCG) rats. Black arrows indicate the reaction direction. The results of steps 1, 2, 3, and 4 steps
lead to disorders of bone metabolism and decreased bone-mineral density.
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mechanisms of calcium deficiency. The correlations
between calcium intake and two of the biomarkers pro-
vide the potential for further assessment and elucidation
of the metabolic responses of calcium deficiency in
humans. After further verification of these two biomar-
kers in large population, we anticipate that these two bio-
markers might be useful for population screening and
clinical diagnosis of calcium deficiency in the future.
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